Form 4: Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Shares

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc., reported the sale of 847 shares of common stock at a weighted average price of $30.003.

Summary

• On October 18, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), sold 847 shares of common stock.
• The sale was executed at a weighted average price of $30.003, with individual trades ranging from $30.00 to $30.03.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following the transaction, Lyssikatos directly owns no shares, but indirectly owns 1,015,188 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The sale could be for various personal financial reasons and doesn't necessarily reflect a negative outlook on the company.

Industry Context

This filing is a routine disclosure of insider trading activity. It provides transparency to the market regarding the transactions of company executives.

Stakeholder Impact

• The sale of shares by a company officer may be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the transaction.

Key Dates